Holen Sie sich die Stockscreener-App
2.41
3.88%
0.09
Jaguar Health Inc Aktie (JAGX) Neueste Nachrichten
What drives Jaguar Health Inc. stock priceMarket-leading profit generation - PrintWeekIndia
Published on: 2025-07-20 16:31:40 - Autocar Professional
What analysts say about Jaguar Health Inc. stockExceptional financial outcomes - Autocar Professional
Jaguar Health Inc. Stock Analysis and ForecastPowerful market insights - Autocar Professional
Is Jaguar Health Inc. a good long term investmentAccelerated wealth expansion - Jammu Links News
Jaguar Health Announces Amendment to March 2020 Equity Purchase Agreement with Oasis Capital, LLC - FinancialContent
Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - Lancaster Eagle-Gazette
Clinical Trial Launches for First FDA-Approved Dog Diarrhea Treatment, Targeting $6B Pet Health Market - Stock Titan
Jaguar Health Eliminates Certain Royalty Obligations Reducing Future COGS for Mytesi and Crofelemer - ACCESS Newswire
Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS In - El Paso Times
Groundbreaking Deal: Peru Grants Access to Sacred Coca Plant for Mental Health Drug Research - Stock Titan
Investors Give Jaguar Health, Inc. (NASDAQ:JAGX) Shares A 36% Hiding - 富途牛牛
Jaguar Health Announces that Orphan Drug Designation Application Submitted to the FDA for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Has Been Accepted for Review - ACCESS Newswire
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Lohud
Investors Give Jaguar Health, Inc. (NASDAQ:JAGX) Shares A 43% Hiding - simplywall.st
Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient - Worcester Telegram
Breakthrough Treatment Reduces Parenteral Nutrition by 27% in Orphan Disease PatientsNew Clinical Data - Stock Titan
Jaguar Health (JAGX) Announces $3.37M At-The-Market Stock Offering | JAGX SEC FilingForm 424B5 - Stock Titan
Jaguar Health (JAGX) Adopts Cryptocurrency as Treasury Asset | JAGX Stock News - GuruFocus
Jaguar Health considers cryptocurrency for treasury reserves - Investing.com
Jaguar Health (JAGX) Targets EU Approval for Canalevia in Dogs | JAGX Stock News - GuruFocus
Jaguar Health Targets 104M Dog EU Market with Novel Diarrhea Treatment as Partnership Talks Heat Up - Stock Titan
Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026 - The Columbus Dispatch
Jaguar Health extends maturity date for $2.57 million in notes By Investing.com - Investing.com Nigeria
Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer - The Holland Sentinel
Jaguar Health reports 25% enrollment in phase 2 MVID study - Investing.com
Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts - Marco Eagle
Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts | JAGX Stock News - GuruFocus
Jaguar Health CEO Reveals Near-Term Catalysts at Emerging Growth Conference Tomorrow - Stock Titan
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - The Oklahoman
Jaguar Health (JAGX) Advances Canalevia-CA1 Field Study for Cani - GuruFocus
First Study Site Established for Jaguar Health Study of its FDA - GuruFocus
1.03%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):